Open AccessTreatment of deep venous thrombosis in pregnant women
Author(s) -
LYKKE JACOB A.,
GRØNLYKKE THOR,
LANGHOFFROOS JENS
Publication year - 2008
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1080/00016340802449118
Subject(s) - medicine , regimen , deep vein , thrombosis , pregnancy , venous thrombosis , anesthesia , surgery , genetics , biology
The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non‐pregnant subjects. In clinical practice, we have experienced a need for a higher dosage, especially in the initial phase of the treatment of deep vein thrombosis, based on four‐hour post‐dose measurements of anti‐Xa activity. Twenty‐two pregnant patients with a confirmed deep venous thrombosis were treated with tinzaparin either in a once‐ or twice‐daily regimen. Four‐hour post‐dosage plasma anti‐Xa activity was measured in 357 sequential blood samples during treatment. An higher dosage than recommended, was required to maintain anti‐Xa activity in the target range. We suggest that the starting dosage should be 250 IU/kg/day in a twice‐daily regimen, and that the dose in the initial phase be adjusted by daily monitoring of anti‐Xa.